Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 294

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

Open access
Tamura, Kenji, Kurihara, Hiroaki, Yonemori, Kan, Tsuda, Hitoshi, Suzuki, Junko, Kono, Yuzuru, Honda, Natsuki, Kodaira, Makoto, Yamamoto, Harukaze, Yunokawa, Mayu, Shimizu, Chikako, Hasegawa, Koki, Kanayama, Yousuke, Nozaki, Satoshi, Kinoshita, Takayuki, Wada, Yasuhiro, Tazawa, Shusaku, Takahashi, Kazuhiro, Watanabe, Yasuyoshi, Fujiwara, Yasuhiro · 2013 · Journal of Nuclear Medicine

Abstract

UNLABELLED: The purpose of this study was to determine the safety, distribution, internal dosimetry, and initial human epidermal growth factor receptor 2 (HER2)-positive tumor images of (64)Cu-DOTA-trastuzumab in humans. METHODS: PET was performed on 6 patients with primary or metastatic HER2-positive breast cancer at 1, 24, and 48 h after injection of approximately 130 MBq of the probe (64)Cu-DOTA-trastuzumab. Radioactivity data were collected from the blood, urine, and normal-tissue samples of these 6 patients, and the multiorgan biodistribution and internal dosimetry of the probe were evaluated. Safety data were collected for all the patients after the administration of (64)Cu-DOTA-trastuzumab and during the 1-wk follow-up period. RESULTS: According to our results, the best timing for the assessment of (64)Cu-DOTA-trastuzumab uptake by the tumor was 48 h after injection. Radiation exposure during (64)Cu-DOTA-trastuzumab PET was equivalent to that during conventional (18)F-FDG PET. The radioactivity in the blood was high, but uptake of (64)Cu-DOTA-trastuzumab in normal tissues was low. In 2 patients, (64)Cu-DOTA-trastuzumab PET showed brain metastases, indicative of blood-brain barrier disruptions. In 3 patients, (64)Cu-DOTA-trastuzumab PET imaging also revealed primary breast tumors at the lesion sites initially identified by CT. CONCLUSION: The findings of this study indicated that (64)Cu-DOTA-trastuzumab PET is feasible for the identification of HER2-positive lesions in patients with primary and metastatic breast cancer. The dosimetry and pharmacologic safety results were acceptable at the dose required for adequate PET imaging.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.112.118612

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 294

Metadata

Authors
Tamura, K., Kurihara, H., Yonemori, K., Tsuda, H., Suzuki, J., Kono, Y., Honda, N., Kodaira, M., Yamamoto, H., Yunokawa, M., Shimizu, C., Hasegawa, K., Kanayama, Y., Nozaki, S., Kinoshita, T., Wada, Y., Tazawa, S., Takahashi, K., Watanabe, Y., & Fujiwara, Y.
Venue
Journal of Nuclear Medicine
Published
2013-09-12
Volume
54
Issue
11
Pages
1869-1875
ISSN
  • 0161-5505 (ISSN-L)
  • 2159-662X
OpenAlex
W1978863320
Cited by
294
References
23
FWCI
18.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer. https://app.cochat.ai/papers/10.2967/jnumed.112.118612
The paper
Tamura, K., Kurihara, H., Yonemori, K., Tsuda, H., Suzuki, J., Kono, Y., Honda, N., Kodaira, M., Yamamoto, H., Yunokawa, M., Shimizu, C., Hasegawa, K., Kanayama, Y., Nozaki, S., Kinoshita, T., Wada, Y., Tazawa, S., Takahashi, K., Watanabe, Y., & Fujiwara, Y. (2013). 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.112.118612

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.